These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26578723)
1. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. Goldwirt L; Chami I; Feugeas JP; Pages C; Brunet-Possenti F; Allayous C; Baroudjian B; Madelaine I; Sauvageon H; Mourah S; Lebbé C Ann Oncol; 2016 Feb; 27(2):363-4. PubMed ID: 26578723 [No Abstract] [Full Text] [Related]
2. Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al. Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Saiag P; Funck-Brentano C Ann Oncol; 2016 Feb; 27(2):364-5. PubMed ID: 26578725 [No Abstract] [Full Text] [Related]
3. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Funck-Brentano C; Saiag P Ann Oncol; 2015 Jul; 26(7):1470-5. PubMed ID: 25899783 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma. Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094 [TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. Sinha R; Larkin J; Gore M; Fearfield L Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403 [TBL] [Abstract][Full Text] [Related]
17. Community experience of vemurafenib for BRAF(V600) melanoma. Hersey P Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506 [No Abstract] [Full Text] [Related]
19. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib. Sibaud V; Chevreau C Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667 [No Abstract] [Full Text] [Related]
20. Zosteriform type in-transit metastasis of melanoma. Tas F Indian J Med Res; 2016 Jul; 144(1):143. PubMed ID: 27834341 [No Abstract] [Full Text] [Related] [Next] [New Search]